Diplomat.is/more. I m Jay.
|
|
- Megan Dora Johns
- 6 years ago
- Views:
Transcription
1 Diplomat.is/more I m Jay. I have chronic lymphocytic leukemia. I m a retired submarine commander, a father, a husband, an avid woodcarver. I bike 20 miles a day. I know the Diplomat Difference. Investor Presentation September 2015 Copyright 2015 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved.
2 Important note This presentation may contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forwardlooking statements. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to, any projections of financial information; any statements about historical results that may suggest trends for our business and results of operations; any statements of the plans, strategies and objectives of management for future operations; any statements of expectation or belief regarding future events, health care developments, or specialty pharmaceutical industry market sizes, shares, trends or growth; and any statements of assumptions underlying any of the foregoing. Any forward-looking statements contained in this presentation are based on management's good-faith belief and reasonable judgment based on current information, and these statements are qualified by important factors, many of which are beyond our control, that could cause our actual results to differ materially from those in the forward-looking statements, including changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control, including but not limited to the following risks related to our business: our ability to adapt to changes or trends within the specialty pharmacy industry; significant and increasing pricing pressure from third-party payors, our relationships with key pharmaceutical manufacturers; our limited history with integrating acquisitions; and the effects of competition. These and other risks and uncertainties associated with our business are described in the prospectus for our proposed follow-on offering, including under the heading Risk Factors. We assume no obligation and do not intend to update these forward-looking statements. In addition to U.S. GAAP financials, this presentation includes certain non-gaap financial measures. These historical and forward-looking non-gaap measures are in addition to, not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. A reconciliation between GAAP and non-gaap measures is included in the appendix to this presentation. Diplomat is a registered trademark of Diplomat Pharmacy, Inc. This presentation also contains additional trademarks and service marks of ours and of other companies. We do not intend our use or display of other companies trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. 1
3 Diplomat continues to deliver on key growth drivers Continue to Gain Share in Core Therapeutic Areas (1) 49% y-o-y revenue growth relative to industry growth of ~20% Continued new limited distribution drug contracts won in 2015 Grow High Margin Businesses (2) 310bps margin expansion y-o-y Focused on growing our specialty infusion platform organically Manufacturer Services Selectively Pursue Strategic Acquisitions Strong financial position to pursue additional strategic acquisitions 5 incremental limited distribution drugs Hep C and Technology (1) Based on $542mm revenues in Q and $808mm revenues in Q (2) Based on 5.5% gross margin in Q and 8.6% gross margin in Q
4 Diplomat s base business continues to gain momentum Improving trends across specialty pharmacy Specialty pharmacy market grew 24% from $63bn in 2013 to $78bn in 2014 driving key milestones and achievements at Diplomat Diplomat grew revenues by 49% from 2Q 14 to 2Q 15 Specialty drug approvals comprised ~50%+ of all FDA drug approvals in ,000+ oncology and immunology drugs in global drug development Recent new drug contracts Oncology Hepatitis C Increased prevalence of limited distribution panels Biosimilars launching in U.S. Cystic Fibrosis Other The majority of which are limited distribution drugs 3
5 with strong financial performance Revenue Gross Profit /Script ($ in millions) ($ in millions) (1) Adjusted EBITDA Gross (2) margin 5.5% 8.6% EBITDA 1.1% 2.8% margin 310 bps expansion 170 bps expansion (1) Based on dispensed scripts only. (2) Gross profit / net sales (i.e., based on dispensed and serviced scripts). 4
6 Company overview 5
7 Diplomat: Largest independent specialty pharmacy Diplomat at a glance Founded: 1975; Headquarters: Flint, MI Employees: ~1,550 FY 2014 revenue: ~$2.2 billion Diversified base of marquee partners Exceptional above market revenue growth ($ in millions) (2) 2014 Market share ($78 billion total market size) (1) Scaled business: National footprint Avella 1% OptumRx/ Catamaran 8% 3% Others 20% Walgreens 10% CVS Health/ Omnicare 33% Express Scripts 25% Pharmacy Locations Arizona California Connecticut Florida Illinois Iowa Massachusetts Michigan Minnesota North Carolina Ohio Pennsylvania (1) Source: Economic Report on Retail, Mail and Specialty Pharmacies, Drug Channel Institute and Morgan Stanley Research (2) Based on mid-point of management s estimate range for FY
8 Journey of a specialty patient Diplomat monitors adherence and collects data for manufacturers Patient visits physician Patient Patient receives drugs Physician Physician writes script Patient Diplomat dispenses drug Payor Diplomat provides: Benefit verification Prior authorization Clinical intervention Payor approves script 7
9 Specialty pharmacy industry continues to show exceptional growth Specialty share of spend growing dramatically (1) Specialty spend under pharmacy benefit to more than double (2) 2012A 2015E 2018E 2012A Diplomat 2% 2018E 70% 30% 58% 42% 50% 50% $51 $51 million billion Traditional 58% $118 billion Traditional Specialty Specialty continues to dominate top 10 drug spend (3) 2014A 2020E 7 out of top 10 9 out of top 10 Source: (1) Specialty Drug Trend Across the Pharmacy and Medical Benefit Artemetrx (2) Economic Report on Retail, Mail and Specialty Pharmacies. (3) Pembroke Consulting analysis of World Preview 2015, Outlook to 2020, EvaluatePharma. 8
10 Limited distribution a central and growing theme in Specialty Benefits to biotech / pharma Completely eliminate or reduce reliance on wholesaler Real-time clinical data Commercialization assistance Improves appropriate utilization What is limited distribution? Targeted channel strategy Provides certain specialty pharmacies with exclusive or preferred dispensing rights to certain drugs Fast-growing trend Benefits to Diplomat Barrier to entry Deeper, and earlier, partnerships with pharma / biotech Increased value proposition to payors Market share opportunity Traditional: Limited: Manufacturer Multiple Wholesalers 65,000 Pharmacies Patient Manufacturer One/few pharmacies Patient Portfolio of over 80 limited distribution drugs, comprising approximately 40% of revenue in 2014, and well positioned for disproportionate growth from future drug approvals Recent unique oncology limited panels Diplomat exclusive or semi-exclusive (2012) (2013) (2014) (2014) DPLO EXCLUSIVE DPLO LARGEST OF 5 DPLO LARGEST OF 4 DPLO EXCLUSIVE Diplomat is an opportunity to invest in pharma / biotech drug pipeline, without the binary risk 9
11 Unique competitive position LARGE PBM / RETAIL PHARMACY Diversification distracts from specialty pharmacy Less flexible / less nimble Singularly focused on specialty High-touch model Flexible and nimble Entrepreneurial culture National reach Scalable infrastructure SMALLER SPECIALTY PHARMACIES Limited scale Most focused on one or a few disease states Fragmented market Consolidation opportunity for Diplomat 10
12 Continue to gain share in core therapeutic areas ($ in billions) Large and high growth Oncology and Immunology are Diplomat's power alley Significant growth expected to continue in the future US Oncology revenue Diplomat CAGR Over 3,000 oncology and immunology drugs in global drug development 45% Oncology / Immunology drugs accounted for ~70% of Diplomat s revenues in 2014 US Immunology revenue (1) Addition of several new limited distribution drugs across these areas since the IPO 27% Rapidly growing Hepatitis C franchise additions of Viekira Pak and Harvoni, and acquisition of Burman s, since the IPO Source: EvaluatePharma and company presentations. (1) Includes all indications as defined by EvaluatePharma under Immunology excluding Multiple Sclerosis. 11
13 Grow high margin businesses Continued expansion into specialty infusion market Grow high margin specialty infusion business Recently announced acquisition of BioRx has significantly higher margins 29% gross margin and ~10% EBITDA margin New drug launches creating product preferencing Competition in specialty space creates discount and rebate opportunities Creates new data and service fees with pharma for high margin revenue Hepatitis C Oncology Specialty generics and biosimilars New generics finally coming to specialty Oncology: Temodar and Xeloda Multiple Sclerosis: Copaxone Emerging biosimilars opportunity expands addressable market for Diplomat (longer term) 12
14 Unique strategic partnerships with leading retailers and health systems Needs / benefits for retail / health systems Traditional drug trend low to mid single digit growth Participate in high growth specialty without having to build expensive infrastructure internally One stop shop for patients / consumers Improve portfolio of wellness solutions How does Diplomat support retail and health system partners? Fee-for-service offering Clinical and administrative support services Patient engagement Adherence programs Integrated with retailers dispensing platforms Private label programs Benefits to Diplomat High margin business Leverage infrastructure Improved value proposition with pharma Pharmacy of choice for limited distribution drugs Diplomat s retail and health system partners Recent wins Strong pipeline of future opportunities 13
15 Recent Acquisitions Acquired Company Consideration Rationale Other June 19, 2015 $94M gross purchase price* $84M cash*, $10M stock ~4.5x CY 2014 EBITDA Hep C dominance in Mid Atlantic Hep C is a fast growing and highly profitable disease state Proprietary technology (HealthTrac) with applicability across Diplomat s Hep C platform Proven management team 50 year old company, run by 2 nd generation pharmacist No marketed sales process Diplomat had a one-off look Lack of auction/marketed process Founder/owner led Management all on board at DPLO April 1, 2015 $272M adjusted purchase price* (~$50M tax benefit) $217M cash*, $105M stock ~11.8x CY 2014 EBITDA One year earnout of $35M (all stock) Adds significant scale to specialty infusion business Provides ability to compete for national contracts Increases exposure to higher margin businesses Addition of new disease states, therapeutic categories & 5 new LD s Lack of auction/marketed process Founder/owner led Management all on board at DPLO June 27, 2014 $68.5 million gross purchase price* $52M cash upfront, $12M stock ~8x CY 2013 EBITDA Two year earnout max. $11.5M (all cash) Strong management team Strong therapy mix: IVIG and Hemophilia Favorable geographic footprint Lack of auction/marketed process Founder/owner led Management all on board at DPLO December 16, 2013 $13.4 million gross purchase price* $12M cash upfront ~6x CY 2013 EBITDA Two year earnout max. $2M (all cash) First DPLO acquisition More than doubled hemophilia/specialty infusion business High margins Lack of auction/marketed process Management all on board at DPLO * Value includes closing working capital adjustments 14
16 Future M&A Interests When considering acquisitions, we look for targets that will potentially benefit Diplomat in one or more of the following ways: Accelerate our higher margin business opportunities Expand into new therapeutic areas and/or geographic regions Enhance our clinical capabilities to improve competitive advantage Access to Limited Distribution drugs Bring new services and technologies under our umbrella Makes DPLO better, not just bigger 15
17 Outstanding financial profile 16
18 How we make money and grow profitability (Illustrative example) How we make money Payors Revenue (1) (AWP Y%) Diplomat COGS (WAC X%) Distributors / pharmaceutical manufacturers Patient Physical drug movement $ flows (1) Note AWP = WAC x 1.20 Drug mix and positive pricing trends are tremendous profit tailwinds for Diplomat Diplomat s 2Q 15 Average Our core focus Traditional Drug Specialty Drug A Specialty Drug B Specialty Drug C Specialty Drug C (10% price incr.) Revenue $100 $3,000 $12,000 $30,000 $33,000 Gross Profit ($) $10 $150 $289 $480 $900 $990 Gross Margin (%) 10% 5% 4% 3% 3% Diplomat mix shift movement over time Positive pricing trends 17
19 Strong financial performance Volume, price and mix all driving superior revenue growth Total Revenue 2010 First Six Months of 2015 ($ in millions) $578 $772 $1,127 $1,515 $2,215 $1,007 $1, A 2011A 2012A 2013A 2014A % growth 53% 34% 46% 34% 46% Natural operating leverage and acquisitions driving EBITDA growth and margin expansion ($ in millions) Adjusted EBITDA 2010 First Six Months of 2015 Infrastructure investments including IT, facilities and personnel $8 $15 $11 $19 $35 $14 $ A 2011A 2012A 2013A 2014A % growth 27% 96% (28%) 75% 86% % margin 1.3% 2.0% 1.0% 1.3% 1.6% First Six MonthsFirst Six Months of 2014 of % 2.4% Note: Historical financials are not pro forma for any acquisitions. 18
20 with continued growth in profitability Several factors drive growth in our Gross Profit / Script (1) : Continued mix shift towards higher price, higher profit drugs (including acquisitions) Favorable pricing trends $250 $167 $148 $71 $93 $97 $116 Gross Profit / Script (1) 2010 First Six Months of A 2011A 2012A 2013A 2014A % growth 12% 31% 4% 20% 44% (2) % margin 7.1% 7.3% 6.2% 5.9% 6.3% 5.9% 7.7% Gross margin expansion opportunities: Recent acquisitions with higher gross margins (%) Fee-for-service/rebate opportunities with pharmaceutical manufacturers Specialty generics and biosimilars (longer term) Note: Financials are not pro forma for BioRx acquisition. (1) Based on dispensed scripts only. (2) Gross profit / net sales (i.e., based on dispensed and serviced scripts). 19
21 Balance Sheet summary (as of June 30, 2015) ($ in millions) Actual Cash $17 Total Debt $191 Shareholders equity $473 Net Debt/Pro Forma EBITDA <2x Modest leverage Ample dry powder for the right opportunities (1) Acquired BioRx on April 1, 2015 for an acquisition price of $384mm ($217mm in cash, $126mm equity issuance and contingent consideration fair valued at $41mm). (2) Amended existing credit facility on April 1, 2015, inclusive of a five-year, $120mm term loan. 20
22 Key investment highlights Taking share in high growth specialty pharmacy sector Unique competitive position with differentiated business model Highly experienced and incentivized management team Outstanding financial profile Multiple avenues to drive strong long term growth 21
23 Appendix 22
24 Diversified therapeutic mix Revenue mix by therapeutic category (FY 2014A) Other 22% Multiple Sclerosis 10% Oncology 48% Immunology 20% 23
25 Reconciliation of Net income (loss) and Adjusted EBITDA Calendar year ending December 31, ($ in millions) 2Q'15 2Q' A 2013A 2012A 2011A 2010A Net income (loss) $3.4 $1.7 $4.8 ($26.1) ($2.6) $9.2 ($7.8) Depreciation & Amortization $8.1 $1.2 $8.1 $3.9 $3.8 $3.1 $2.2 Interest Expense $1.9 $0.4 $2.5 $2.0 $1.1 $0.6 $0.5 Income tax expense $2.3 $0.7 $ EBITDA $15.6 $4.0 $20.1 ($20.2) $2.3 $12.8 ($5.2) Share-based compensations expense (1) $0.7 $0.9 $2.9 $0.9 $0.9 $1.4 $0.8 Change in fair value of redeemable common shares ($0.9) ($9.1) $34.3 $6.6 $10.7 Termination of existing stock redemption agreement $4.8 Employer payroll taxes - option repurchases $0.6 - Restructuring and impairment charges $1.0 $0.4 $0.4 $1.5 (3) Equity loss of non-consolidated entity - $0.3 $6.2 $1.1 $0.3 $0.1 - (4) Severance and related fees $0.1 $0.0 $0.4 $0.2 $0.4 $0.7 - (5) Merger and acquisition related expenses $5.3 $1.1 $7.2 $ Private company expenses - - $0.2 $0.2 Tax credits and other - $0.1 $1.0 - ($0.1) ($0.6) - (8) (7) (6) (2) Other items $0.4 $0.4 $1.4 $0.7 $0.1 $0.2 ($0.0) Adjusted EBITDA $22.7 $5.9 $35.2 $19.0 $10.9 $15.1 $7.7 Note: Financials are not pro forma for BioRx acquisition. Detailed footnotes on the following page. 24
26 Reconciliation of Net income (loss) and Adjusted EBITDA 1) Share-based compensation expense relates to director and employee share-based awards. (2) Restructuring and impairment charges reflect decreases in the fair market value of non-core property and assets, or actual losses on disposal of such assets charges primarily relate to the $932 write-down of our former Swartz Creek, Michigan headquarters facility to its fair value, after we vacated it in favor of our present Flint, Michigan facility charges primarily relate to our write-down of an externally purchased software package we no longer utilize, as well as sales of Company-owned vehicles charges include expense associated with the closure of our former Cleveland, Ohio facility, the move of our Chicago, Illinois area facility, and sales of Company-owned vehicles. (3) During the fourth quarter of 2014, we reassessed the recoverability of our investment in our non-consolidated entity, Ageology. Based upon this assessment, we determined that a full impairment of $4,869 was warranted, primarily due to updated projections of continuing losses into the foreseeable future. The remaining amounts in 2014, 2013 and 2012 represents our share of losses recognized by Ageology, using the equity method of accounting. We first invested in Ageology, an anti-aging physician network dedicated to nutrition, fitness and hormones, in October 2011, in connection with its formation. (4) Employee severance and related fees primarily relates to severance for former management. (5) Fees and expenses directly related to merger and acquisition activities, and the impact of changes in the fair value of related contingent consideration liabilities. (6) Primarily includes philanthropic activities performed at the direction of our majority shareholder. (7) Represents (a) various tax credits received from the state of Michigan for facility improvement and employee hiring initiatives, (b) the one-time costs associated with converting from an S-Corporation to a C-Corporation, and (c) a 2014 charge of $1,825 related to non-income tax obligations. (8) Includes other expenses, predominantly IT operating leases. These operating leases were initiated, in lieu of purchases or capital leases for a subset of our IT spend, for a short period of time in 2013 and 2014 for liquidity purposes. We have since discontinued the practice of leasing IT equipment. The cost of purchased IT equipment is reflected in depreciation and amortization. 25
Capturing the Opportunity
Capturing the Opportunity NOVEMBER 2017 BETHANY DIPLOMAT PATIENT Copyright 2017 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. 1 DISCLAIMERS
More informationCapturing the Opportunity
Capturing the Opportunity JANUARY 2018 BETHANY DIPLOMAT PATIENT Copyright 2018 by Diplomat Pharmacy Inc. Diplomat is a registered trademark of Diplomat Pharmacy Inc. All rights reserved. 1 SPECIALTY DRUGS
More informationDIPLOMAT PHARMACY, INC.
DIPLOMAT PHARMACY, INC. FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 4100 S. SAGINAW ST. FLINT, MI 48507 Telephone 888-720-4450 CIK 0001610092 Symbol DPLO SIC
More informationDiplomat s Acquisition of LDI Integrated Pharmacy Services. Nov. 15, 2017
Diplomat s Acquisition of LDI Integrated Pharmacy Services Nov. 15, 2017 1 DISCLAIMERS NON-GAAP INFORMATION We define Adjusted EBITDA as net income (loss) before interest expense, income taxes, depreciation
More informationDiplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance
NEWS RELEASE Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance 2/26/2018 4th Quarter Revenue of $1,155 Million, Net Income Attributable to Diplomat of $6.5 Million,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationStanding strong for payers and patients
Standing strong for payers and patients Eric Slusser, EVP, Chief Financial Officer Everett Neville, SVP Supply Chain and Specialty B A N K O F A M E R I C A M E R R I L L L Y N C H H E A LTH C A RE CONFERENCE
More informationMeeting the Health Care Challenges of Tomorrow. Jon Roberts Executive Vice President & President, CVS Caremark
Meeting the Health Care Challenges of Tomorrow Jon Roberts Executive Vice President & President, CVS Caremark Agenda PBMs: Needed Now More Than Ever Performance Highlights How We Address Payors #1 Priority:
More informationJune Investor Presentation
June 2014 Investor Presentation Safe Harbor Certain statements included herein, including guidance and those that express management's objectives and the strategies to achieve those objectives, as well
More informationStanding strong for payers and patients
Standing strong for payers and patients Dr. Steve Miller, SVP, Chief Medical Officer Ben Bier, VP Investor Relations W I L L I A M B L A I R 3 7 TH ANNUAL G ROWTH STOCK C ONFERENCE 6.14.17 1 Safe harbor
More informationWilliam Blair Growth Stock Conference June 15, Member FINRA/SIPC
William Blair Growth Stock Conference June 15, 2011 Member FINRA/SIPC Safe Harbor Disclosure The following information contains forward-looking statements. Forward-looking statements include statements
More informationJP Morgan Healthcare Conference January 13, 2016
JP Morgan Healthcare Conference January 13, 2016 FORWARD-LOOKING STATEMENTS Certain statements and information in this presentation may be deemed to be forward-looking statements within the meaning of
More informationBaird Global Healthcare Conference
Baird Global Healthcare Conference Jason Meggs Chief Financial Officer September 6, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 8, 2019 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking
More informationMagellan Health. Cantor Fitzgerald Healthcare Conference September 26, 2017
Magellan Health Cantor Fitzgerald Healthcare Conference September 26, 2017 Cautionary Statement and Non-GAAP measures 2 This slide presentation and our accompanying oral comments include forward-looking
More informationRaymond James 37 th Annual Institutional Investors Conference. March 8, 2016
Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,
More informationCIGNA AND EXPRESS SCRIPTS: EXPANDS GROWTH OPPORTUNITIES IMPROVES AFFORDABILITY CREATES DIFFERENTIATED SHAREHOLDER VALUE
CIGNA AND EXPRESS SCRIPTS: EXPANDS GROWTH OPPORTUNITIES IMPROVES AFFORDABILITY CREATES DIFFERENTIATED SHAREHOLDER VALUE March 2018 Important Information for Investors and Shareholders FORWARD LOOKING STATEMENTS
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationPharmacy Benefit Management in Oncology
Pharmacy Benefit Management in Oncology October 28 th, 2015 Business Health Care Group Protecting the Future of Oncology Care: A Community Conversation Brent Eberle RPh MBA Chief Pharmacy Officer, Navitus
More informationPharmaceutical Market Trends
Pharmaceutical Market Trends External research and findings Alex Jung 2017 Alex Jung Partner/Managing Director Direct: 312-879-2778 Mobile: 847-722-3482 Email: Alex.Jung@ey.com Office: 155 N Wacker Drive,
More informationAcquisition of Dealer Inspire and Launch Digital Marketing
Acquisition of Dealer Inspire and Launch Digital Marketing Investor Presentation February 14, 2018 Forward Looking Statements This presentation contains forward looking statements within the meaning of
More informationFourth Quarter 2018 Earnings Conference Call
Fourth Quarter 2018 Earnings Conference Call Larry Merlo President & Chief Executive Officer Eva Boratto Executive Vice President & Chief Financial Officer February 20, 2019 Cautionary Statement Regarding
More informationGrowth in an Evolving Health Care Market
Driving Enterprise Growth in an Evolving Health Care Market Larry Merlo President & Chief Executive Officer Agenda Our Compelling Value Proposition Evolving Health Care Market Creates Opportunities Strategic
More informationWhat to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019
What to Expect for Pharmacy Benefits and Drug Cost Trends for 2018 & 2019 Mid-Sized Retirement and Healthcare Plan Management Conference 2018. Innovative Rx Strategies, LLC. All rights reserved. The Ever
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 15, 2014 Greg Wasson President and CEO 2 1 Safe Harbor and Non-GAAP Certain statements and projections of future results made in these presentations constitute
More informationSafe Harbor Statement
January 3, 2018 Safe Harbor Statement Statements in this presentation that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationSurgical Care Affiliates, Inc. 32 nd Annual J.P. Morgan Healthcare Conference. January 2014
Surgical Care Affiliates, Inc. 32 nd Annual J.P. Morgan Healthcare Conference January 2014 Disclaimer Certain statements herein are forward-looking statements made pursuant to the safe harbor provisions
More information~400 SIGNIFICANT CLIENTS ~700 PRODUCTS 70+ COUNTRIES 75% OF ALL DOSAGE FORMS 21% ALL OUTSOURCED FDA APPROVALS IN LAST DECADE 95%+ RFT/OTD
~400 SIGNIFICANT CLIENTS ~700 PRODUCTS 70+ COUNTRIES JP Morgan Healthcare Conference Click to edit Master title style San Francisco, CA Click to edit July Master 11, 2016 text January 9, 2016 styles 75%
More informationJames C. Robinson Kaiser Permanente Professor of Health Economics Director, Berkeley Center for Health Technology University of California, Berkeley
James C. Robinson Kaiser Permanente Professor of Health Economics Director, Berkeley Center for Health Technology University of California, Berkeley Public policy: Congress and Obama Administration Challenges
More informationPowering healthcare provider success
Powering healthcare provider success Now and in the future Investor Information September 2018 TRANSFORMING HEALTHCARE TOGETHER Premier Inc. 2018 1 Forward-looking statements and non-gaap financial measures
More informationMedicaid in a Time of Historic Change: Prescription Drugs and Costs A Medicaid Perspective
Medicaid in a Time of Historic Change: Prescription Drugs and Costs A Medicaid Perspective Presented to NCSL Legislative Summit August 9, 2016 Steve Fitton, Principal at Health Management Associates rev
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationCBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting
CBI 4th Reimbursement and Contracting Conference: Key Challenges Related to Specialty Drug Pricing and Contracting Avalere Health An Inovalon Company February 28, 2017 Growth in Drug Costs Relative to
More informationCantor Fitzgerald 2017 Global Healthcare Conference. September 26, 2017
Cantor Fitzgerald 2017 Global Healthcare Conference September 26, 2017 Forward-Looking Statements and Non-GAAP Financial Measures This presentation contains forward-looking statements, including statements
More informationReducing Costs, Improving Quality, Reinventing Healthcare
Reducing Costs, Improving Quality, Reinventing Healthcare J.P. Morgan Healthcare Conference 01.09.19 2018. All rights reserved. Premier Inc. Forward-looking statements and non-gaap financial measures Forward-looking
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationSyneos Health. Q4 and Full Year 2017 Financial Results. February 28, 2018
Syneos Health Q4 and Full Year 2017 Financial Results February 28, 2018 Forward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the
More informationDelivering Value for All Health Care Stakeholders. Larry Merlo President & Chief Executive Officer
Delivering Value for All Health Care Stakeholders Larry Merlo President & Chief Executive Officer Agenda Our Value Proposition Has Never Been Stronger We See Compelling Opportunities in a Robust Health
More information36 th Annual J.P. Morgan Healthcare Conference. January 10, 2018
36 th Annual J.P. Morgan Healthcare Conference January 10, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute forward-looking statements,
More informationFirst Quarter 2016 Earnings
First Quarter 2016 Earnings Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995.
More informationFBM 2Q18 Earnings Presentation
FBM 2Q18 Earnings Presentation August 9, 2018 DISCLOSURES Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform
More informationMcKesson Corporation J.P. Morgan Healthcare Conference
McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer Forward-Looking Statements Some of the information in this presentation is not historical in
More informationAmerisourceBergen. CECP CEO Investor Forum Steve Collis, Chairman, President & CEO. February 25, 2019
AmerisourceBergen CECP CEO Investor Forum Steve Collis, Chairman, President & CEO February 25, 2019 Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation
More informationEndo International plc
Endo International plc Q2 2015 Earnings Report August 10, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationThird Quarter 2017 Earnings Conference Call
Third Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer November 6, 2017 Forward-looking Statements This
More informationFourth Quarter and Full Year 2017 Results. March 1, 2018
1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of
More informationFourth Quarter 2017 Earnings Conference Call
Fourth Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer February 8, 2018 Important Information No Offer
More informationPowering healthcare provider success
Powering healthcare provider success Now and in the future 38 th Annual William Blair Growth Stock Conference June 12, 2018 TRANSFORMING HEALTHCARE TOGETHER Premier Inc. 2018 1 Forward-looking statements
More informationReducing Costs, Improving Quality, Reinventing Healthcare
Reducing Costs, Improving Quality, Reinventing Healthcare Investor Information January 2019 2018. All rights reserved. Premier Inc. Forward-looking statements and non-gaap financial measures Forward-looking
More informationFEEL BETTER. CONNECTED.
FEEL BETTER. CONNECTED. Connected across pharmacy and medical. To take you further. Katy Wong, RPh, MBA Vice President, Producer Relations Cigna Pharmacy Management Offered by: Cigna Health and Life Insurance
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More informationMcKESSON REPORTS FISCAL 2015 THIRD-QUARTER RESULTS
McKESSON REPORTS FISCAL 2015 THIRD-QUARTER RESULTS Revenues of $47 billion for the third quarter, up 37%. Third-quarter GAAP earnings per diluted share from continuing operations of $2.01, up 187%. Third-quarter
More informationSecond Quarter 2017 Earnings Conference Call
Second Quarter 2017 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer August 8, 2017 Forward-looking Statements This
More informationSyneos Health. Q Financial Results. August 2, 2018
Syneos Health Q2 2018 Financial Results August 2, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements Except for historical information,
More informationImportant Information for Investors and Stockholders
March 1, 2010 Important Information for Investors and Stockholders This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any
More informationFOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018
FOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018 0 Agenda and Speakers Joe Woody Chief Executive Officer Halyard Outlook and Update on Divestiture 2018 Priorities Steve Voskuil Chief Financial Officer
More informationPrescription Drugs (Rx) Fast Facts
HEALTH SEMINAR FOR NEWER LEGISLATORS Prescription Drugs Session Sunday April 15, 2018 Richard Cauchi, Program Director, NCSL Health Program Prescription Drugs (Rx) Fast Facts More than half of all Americans
More informationWalgreens Boots Alliance 2015 analyst meeting financial session. Safe Harbor and Non-GAAP
Walgreens Boots Alliance 2015 analyst meeting financial session 16 April 2015 Safe Harbor and Non-GAAP Certain statements and projections of future results made in this presentation constitute forward-looking
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationDaVita HealthCare Partners. J.P. Morgan Healthcare Conference January 8, 2013
DaVita HealthCare Partners J.P. Morgan Healthcare Conference January 8, 2013 Certain statements in today s presentation contain forward-looking statements within the meaning of the federal securities laws.
More informationInnovative Strategies for Managing the Rising Cost of Specialty Drugs
Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs
More informationInvestor Presentation. Second Quarter 2018 NASDAQ: BECN BECN
Investor Presentation Second Quarter 2018 BECN 1 Disclosures Forward Looking Statements and Non-GAAP Measures This presentation contains forward-looking statements within the meaning of the Private Securities
More informationFourth Quarter and Full Year 2017 Results Presentation February 23, 2018
Fourth Quarter and Full Year 2017 Results Presentation February 23, 2018 General Disclosure This presentation includes forward-looking statements within the meaning of Section 27A of the U.S. Securities
More informationSS&C Technologies (NASDAQ:SSNC)
SS&C Technologies (NASDAQ:SSNC) Leading Software Provider to the Institutional, Alternative and Wealth Management Markets SS&C to Acquire DST Systems January 11, 2018 Safe Harbor Statement Safe Harbor
More informationForward-Looking Statements
William Blair & Company 27 th Annual Growth Stock Conference June 20, 2007 0 Forward-Looking Statements This presentation contains forward-looking statements that are subject to a number of risks and uncertainties,
More informationInvestor Presentation. August 2007
Investor Presentation August 2007 Forward-Looking Statement This presentation should be considered forward-looking and is subject to various risk factors and uncertainties. For more information on those
More informationNLSN 4Q and FY 2011 Investor Presentation
NLSN 4Q and FY 2011 Investor Presentation Forward Looking Statements The following discussion contains forward-looking statements, including those about Nielsen s outlook and prospects, in the meaning
More informationJEFFERIES GLOBAL HEALTHCARE CONFERENCE
JEFFERIES GLOBAL HEALTHCARE CONFERENCE November 20, 2014 2014 PAREXEL INTERNATIONAL CORP. ALL RIGHTS RESERVED. SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference John J. Greisch, President and CEO January 9, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform
More information35th Annual J.P. Morgan Healthcare Conference. January 12, 2017
35th Annual J.P. Morgan Healthcare Conference January 12, 2017 Safe Harbor Statement and Non-GAAP Financial Measures This presentation contains forward-looking statements, including statements regarding
More informationUnique PBM Capabilities
Gaining Lives With Our Unique PBM Capabilities Jon Roberts Executive Vice President & President, CVS/caremark Agenda Performance Highlights Pharmacy Trends and Cost Management Programs Well Positioned
More informationExpress Scripts Announces 2018 First Quarter Results
Contact: Jim Havel, Chief Financial Officer Ben Bier, Vice President, Investor Relations (314) 810-3115 investor.relations@express-scripts.com Express Scripts Announces 2018 First Quarter Results ST. LOUIS,
More informationLannett Company, Inc. Kremers Urban Acquisition September 2, 2015
Lannett Company, Inc. Kremers Urban Acquisition September 2, 2015 Forward Looking Statements Except for historical facts, the statements in this presentation, as well as oral statements or other written
More informationPatrick J. Sullivan Chief Executive Officer. March 5, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer March 5, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationEarnings Conference Call
First Quarter 2015 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer May 1, 2015 Forward-looking Statements During
More information34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO
34 th Annual J.P. Morgan Healthcare Conference Steve Collis, President & CEO Tim Guttman, EVP & CFO January 12, 2016 Steve Collis President & CEO Cautionary Note Regarding Forward-Looking Statements Certain
More informationCWAG Prescription Drug Pricing Webinar
CWAG Prescription Drug Pricing Webinar January 9, 2018 Kipp Snider, J.D. Vice President, State Policy Pharmaceutical Research & Manufacturers of America (PhRMA) Medicines Are Expected to Account for a
More informationOur Transformation Continues Sidoti NDR May 29-30, 2018
Our Transformation Continues Sidoti NDR May 29-30, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation,
More informationForward Looking Statements
Third Quarter 2018 Results and Acquisition of USAA Asset Management Company November 7, 2018 Forward Looking Statements This presentation may contain forward-looking statements that are based on our beliefs
More informationVantiv Investor Presentation
Vantiv Investor Presentation February 1, 2017 2015 Vantiv, LLC. All rights reserved. Disclaimer This presentation contains forward-looking statements that are subject to risks and uncertainties. All statements
More informationEndo Health Solutions
Endo Health Solutions 3Q 2013 Earnings Report and A Compelling Combination: Endo Health Solutions and Paladin Labs November 5, 2013 Offer Language Disclosures This communication is not intended to and
More information(Unaudited) Reconciliation GAAP to Non-GAAP (In thousands) Pro Forma As Adjusted. Pro Forma Adjustments. Pro Forma As Adjusted. Pro Forma Adjustments
Supplemental Presentation of Selected Quarterly Non-GAAP Financial Information for Fiscal Years 2014-2015, Including Proforma Related to Automotive Business Divesture and Reconciliation to GAAP As announced
More informationCIBC World Markets 2 nd Annual Mid & Small Cap Best Ideas Conference November 2006
CIBC World Markets 2 nd Annual Mid & Small Cap Best Ideas Conference November 2006 Introduction Note: This presentation is North America - focused and therefore excludes the recent acquisition of Wiron
More informationEarnings. Larry Merlo. President & Chief Executive Officer. Executive Vice President & Chief Financial Officer. November 4, 2014
Third dquate Quarter Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer November 4, 2014 Forward-looking Statements
More informationAltice USA Q4 and Full-Year 2018 Results. February 21, 2019
Altice USA Q4 and Full-Year 2018 Results February 21, 2019 Disclaimer FORWARD-LOOKING STATEMENTS Certain statements in this presentation constitute forward-looking statements within the meaning of the
More informationCowen and Company 37 th Annual Health Care Conference. March 6, 2017
Cowen and Company 37 th Annual Health Care Conference March 6, 2017 Safe Harbor Statement and Non-GAAP Financial Measures This presentation contains forward-looking statements, including statements regarding
More informationINVESTOR PRESENTATION Worldpay, Inc. All rights reserved.
INVESTOR PRESENTATION 1 DISCLAIMER No Offer or Solicitation This presentation is provided for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation
More informationREV GROUP, INC. S e p te m b e r I nv e s t o r P re s e nt a t i o n N Y S E : R E V G September 2018
REV GROUP, INC. September Investor Presentation N Y S E : R E V G September 2018 Cautionary Statements & Non GAAP Measures Disclaimers Note Regarding Non-GAAP Measures REV Group reports its financial results
More information2017 WELLS FARGO HEALTHCARE CONFERENCE
2017 WELLS FARGO HEALTHCARE CONFERENCE September 7, 2017 TRANSFORMING HEALTHCARE TOGETHER UNIQUELY POSITIONED FOR THE FUTURE 2017 1 Craig McKasson Chief Financial Officer Premier Inc. TRANSFORMING HEALTHCARE
More informationSafe Harbor Statement
June 27, 2018 Safe Harbor Statement Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical, are forward-looking statements made pursuant to the
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationCatalent, Inc. Jefferies Global Healthcare Conference. June 9, DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied.
Catalent, Inc. Jefferies Global Healthcare Conference June 9, 2016 DEVELOPMENT DELIVERY SUPPLY more products. better treatments. reliably supplied. Disclaimer Statement Forward-Looking Statements This
More informationInvestor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE
Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH
More informationFourth Quarter and Fiscal 2016 Results. 20 October 2016
Fourth Quarter and Fiscal 2016 Results 20 October 2016 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that
More information3 rd Quarter Fiscal 2019
3 rd Quarter Fiscal 2019 SUPPLEMENTAL INFORMATION December 19, 2018 SAFE HARBOR STATEMENT Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical,
More informationPress Release INVESTOR RELATIONS CONTACT: MEDIA CONTACT: Will McDowell 215-761-4198 william.mcdowell2@cigna.com Ellie Polack 860-902-4906 elinor.polack@cigna.com Cigna Delivers Strong 2018 Results as it
More information